TP53 mutations are rare at the time of diagnosis and the CP phase of CML [394, 395]; however, they were present in approximately 15%-30% of the CML patients in BC [396]. This evidence concerns the gene TP53 and chronic myelogenous leukemia, BCR-ABL1 positive.